Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis
© Meier et al. licensee BioMed Central Ltd. 2009
Received: 09 February 2009
Accepted: 13 May 2009
Published: 13 May 2009
Skip to main content
© Meier et al. licensee BioMed Central Ltd. 2009
Received: 09 February 2009
Accepted: 13 May 2009
Published: 13 May 2009
Contrast-induced nephropathy is the leading cause of in-hospital acute renal failure. This side effect of contrast agents leads to increased morbidity, mortality, and health costs. Ensuring adequate hydration prior to contrast exposure is highly effective at preventing this complication, although the optimal hydration strategy to prevent contrast-induced nephropathy still remains an unresolved issue. Former meta-analyses and several recent studies have shown conflicting results regarding the protective effect of sodium bicarbonate. The objective of this study was to assess the effectiveness of normal saline versus sodium bicarbonate for prevention of contrast-induced nephropathy.
The study searched MEDLINE, EMBASE, Cochrane databases, International Pharmaceutical Abstracts database, ISI Web of Science (until 15 December 2008), and conference proceedings for randomized controlled trials that compared normal saline with sodium bicarbonate-based hydration regimen regarding contrast-induced nephropathy. Random-effects models were used to calculate summary odds ratios.
A total of 17 trials including 2,633 subjects were pooled. Pre-procedural hydration with sodium bicarbonate was associated with a significant decrease in the rate of contrast-induced nephropathy (odds ratios 0.52; 95% confidence interval 0.34–0.80, P = 0.003). Number needed to treat to prevent one case of contrast-induced nephropathy was 16 (95% confidence interval 10–34). No significant differences in the rates of post-procedure hemodialysis (P = 0.20) or death (P = 0.53) was observed.
Sodium bicarbonate-based hydration was found to be superior to normal saline in prevention of contrast-induced nephropathy in this updated meta-analysis.
Contrast agents are administered to millions of procedures annually worldwide. In the USA and Europe, contrast-induced nephropathy (CIN) is the third leading cause of acute renal failure in hospitalized patients, accounting for about 10% of hospital-acquired renal failure . The issue of contrast agent-related risk further gains importance with the growing awareness that even gadolinium-based agents are not harmless and may induce renal damage .
Two mechanisms have been hypothesized to be responsible for CIN development: contrast media-triggered vasoconstriction and development of oxidative stress, that is, intrarenal accumulation of reactive oxygen species. One major underlying hypothesis for application of sodium bicarbonate (NaHCO3) is that the alkalinization of tubular fluid diminishes the production of free oxygen radicals [3, 4]. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute ischemic renal failure .
Previous meta-analyses have shown a significant benefit for NaHCO3 in comparison to normal saline (NS) infusion [6, 7], although they highlighted the possibility of publication bias. Two trials published thereafter did not show an advantage of NaHCO3 [8, 9], while multiple smaller studies have published preliminary but rather contradictory results [10, 11]. A recent retrospective study suggested even possible harm of NaHCO3 . Given these conflicting results, an updated meta-analysis is meaningful. The purpose of this study was to evaluate the current published and unpublished data regarding the use of NaHCO3 versus NS as pre-procedural hydration for the prevention of CIN.
We searched PubMed, MEDLINE, the Cochrane Central Register of Controlled Trials, International Pharmaceutical Abstracts database, and ISI Web of Science and google scholar from 1990 through to 15 December 2008. In addition, abstract lists and conference proceedings from the 2007 and 2008 scientific meetings of the American College of Cardiology, the European Society of Cardiology, the Transcatheter Cardiovascular Therapeutics, the American Heart Association, the American Society of Nephrology, the European Renal Association, the annual meeting of the Radiology Society of North America Annual, and the World Congress of Cardiology were searched. We also considered published review articles, editorials, and internet-based sources of information (http://www.tctmd.com, http://www.theheart.org) to assess for potential information on studies of interest. Medical subject headings and keyword searches included the terms 'contrast nephropathy', 'sodium bicarbonate', 'saline infusion', 'radiocontrast', and 'renal failure'. Reference lists of selected articles were reviewed for other potentially relevant citations. Authors of selected studies were contacted to obtain further information.
Two reviewers (PM and UT) extracted relevant information from the articles including baseline clinical characteristics of the study population, laboratory data, baseline creatinine, amount of NS infusion in the control group (total and before contrast administration), type of contrast, average contrast volume and data on primary (CIN) and secondary outcomes, such as mortality, need for hemodialysis (HD). CIN was defined differently by each study, but most described it as an absolute or relative increase in serum creatinine. Seven studies defined CIN as a rise in serum creatinine by 25% or more within 2 to 5 days of contrast exposure [15–21]. Two studies regarded an absolute increase of creatinine of 0.5 mg/dl (= 44 μmol/liter) as their primary definition of CIN [9, 22], whereas six authors used a composite definition of either a 25% relative creatinine increase or an absolute increase of 0.5 mg/dl [8, 11, 23–26]. One study  used change in glomerular filtration rate as the primary endpoint and change in creatinine as a secondary definition for CIN and one abstract  did not mention the CIN definition. For each study we used the corresponding predefined primary endpoint. We assessed trial quality by evaluating specific criteria (concealment of allocation during randomization, intention-to-treat analysis, and blinded assessment of outcome measures), but did not use a quality score in regard to the limitations inherent in such an approach .
Data from all the selected studies were combined to estimate the pooled odds ratio (OR) of effect sizes for NS compared with NaHCO3 using a random-effects model. All analyses were performed on an intention-to-treat basis. Continuity correction was used when an event did not occur in one group . Significant between-study heterogeneity was expected regarding study populations, therefore a random-effects model was used to produce across-study summary OR with 95% confidence intervals (CI). We evaluated the presence of heterogeneity across trials with the Q and I2 statistics, with an I2 value > 50% indicating at least moderate statistical heterogeneity. To assess the effect of individual studies on the summary estimate of effect, we did an influence analysis, in which the pooled estimates were recalculated by omitting one study at a time. We assessed publication bias visually (funnel plot) and by formal tests (rank order correlation  and Egger's test of intercept ). A Funnel plot depicts the effect estimates from each trial against study sample size or precision. In absence of publication bias, this plot should appear approximately symmetrical. The Funnel plot is based on the fact that large trials can estimate effects more precisely while smaller trials show wider scattering. A formal measure of Funnel plot asymmetry is the Egger test. It is a linear regression of normalized effects (effect divided by its standard error (SE)) against precision (reciprocal SE of the effect). Very small studies have a larger SE and, consecutively, a normalized effect and a precision that is close to zero. Therefore, the intercept of the regression comes close to zero; if it significantly differs from zero, this indicates systematic deviance of the effect of small studies (small study effect and/or bias, for example, due to publication bias).
We also calculated fail-safe N (that is, the number of studies required to nullify the significant differences in CIN between the two groups) using Rosenberg's and Orwin's method [32, 33]. As there was a suggestion of publication bias, Duval and Tweedie's  Trim and Fill method was used to calculate imputed OR for CIN. Exploratory meta-regression based on a mixed-effect model was performed to estimate the extent to which selected covariates that potentially influence risk for CIN could explain the observed heterogeneity of the NaHCO3 effect (average age of patients, baseline creatinine, volume of contrast medium used, prevalence of diabetic patients in the study, and amount of NS infusion before contrast administration in the control group). Stratified analysis was performed to assess the effect of NaHCO3-based hydration in select groups (patients treated with low osmolar versus iso-osmolar contrast, and those undergoing elective versus emergent procedures) and to assess impact of published versus unpublished studies. All analyses were performed using Comprehensive Meta-Analysis software, version 2.0 (Biostat, Englewood, NJ, USA) and MIX, version 1.7 .
A total of 184 articles were reviewed, and 17 studies satisfied the predetermined inclusion criteria (Figure 1) [8–11, 15–27]. Eight trials have been published in the peer-reviewed literature whereas another nine studies are as yet unpublished but were presented at scientific meetings (that is, Transcatheter Therapeutics meeting, American Heart Association meeting, American Society of Nephrology meeting, World Congress of Cardiology, or Canadian Cardiovascular Congress). Further information on these unpublished trials was obtained from the study authors where possible. One study randomized patients to three arms: NaHCO3, NS, or NS and NAC. From this trial, we used data only from the NaHCO3 and NS arms and excluded the patients randomized to the NS and NAC arm . Data from studies using a 2 × 2 factorial-design testing the influence of NAC and the effect of NaHCO3 were used by pooling patients from the NaHCO3 and NS arms (with or without NAC) [18, 26]. Additional file 1 summarizes the characteristics of the 17 trials, including a total of 2,633 subjects.
Incidence of contrast-induced nephropathy in treatment arms.
CIN incidence NaHCO3 (%)
CIN incidence NS (%)
There was moderate heterogeneity across studies regarding clinical patient characteristics and protocols, and also formal tests (I2 = 48.0; Q = 30.6; P value = 0.015).
The Trim and Fill method was used to calculate a treatment effect based on imputed estimated unpublished studies. The imputed OR for CIN using the random-effects model was 0.62 (95% CI 0.40–0.97). The classic fail-safe N was 67, suggesting that 67 additional negative studies would be needed to negate the results of our meta-analysis. A much more conservative variant of this method, the Orwin's fail-safe N, assumes that unpublished or future studies are not simply negative but rather in disfavor of NaHCO3. Under the very conservative assumption of a mean OR of 2.7 in unpublished studies (as observed in the included trial with the most extreme result ), eight such trials would be necessary to nullify the overall beneficial effect of NaHCO3.
The need for HD was reported in 12 studies (N = 2,011), in five of these, there was no HD event in either group [8, 16, 19, 20, 23]. Overall, 6 out of 934 patients treated with NaHCO3 underwent HD (range 0% to 3.3%) compared with 12 out of the 927 patients treated with NS (range 0% to 10.3%). This difference was not statistically significant (OR 0.53; 95% CI 0.20–1.41, P = 0.20).
Data for mortality were available from seven studies (N = 1,334). In three studies, no death was observed in either group [11, 19, 23]. There were a total of eight deaths in the 886 patients treated with NaHCO3 (range 0% to 1.8%) and 12 in the 666 patients treated with NS (range 0% to 7.3%). The overall-mortality risk was not significantly different between the two treatment groups (OR 0.74; 95% CI 0.29–1.9, P = 0.53).
In this meta-analysis of 17 RCTs including 2,633 patients, pre-procedural hydration with NaHCO3 reduced the incidence of CIN compared with hydration with NS. Our findings thus corroborate and extend the prior meta-analysis in the field. Our findings were based on a larger number of trials, include a much larger patient population and adjusted for publication bias by including multiple unpublished studies.
Although CIN is generally limited to a transient decline of renal function, it can not be regarded as a benign complication. Some degree of residual renal impairment has been reported in as many as 30% of those affected by CIN . In an observational study of patients undergoing percutaneous coronary intervention, dialysis was started in 0.8%; persistent renal failure requiring permanent dialysis developed in 13% of these patients ; in patients with diabetes and severe renal failure the rate of dialysis was even higher . CIN is associated with a prolonged hospital stay and corresponding additional costs [8, 17], and it portends a high morbidity and an increased in-hospital and long-term mortality [39–43]. Acute renal insufficiency leads to increased myocardial oxygen consumption and impaired vascular function in dogs  and it is plausible that similar mechanisms may be applicable in humans.
However, this diminished risk for CIN seems not to translate into a decreased incidence of death or need for HD in this current meta-analysis. A similar phenomenon has also been reported in studies evaluating NAC . Several reasons may account for this disconnection between CIN and need for renal replacement therapy or mortality. The patient population enrolled in these studies was generally young and at low risk of adverse events, and very few studies provide long-term follow-up data. The incidence of mortality and need for HD was low in general. Given such low event rates, even a pooled analysis is underpowered to detect a significant difference. Furthermore, it is possible that the definitions of CIN used in these studies are too sensitive regarding the prediction of adverse outcome. Finally, contrast media may impair tubular creatinine excretion, which could lead to an underestimation of the renal function when using creatinine as a surrogate . Importantly, while not significant statistically, the incidence of both death and need for renal replacement therapy was lower in the NaHCO3 arm.
While the overall results of the meta-analysis and the imputed OR favors use of NaHCO3, possible reasons for heterogeneity must be considered. The study populations and the study settings were rather variable. Stratified analyses revealed differences between NaHCO3 effects in emergency and elective cases as one potential reason for the heterogeneity. Interestingly, the benefit of NaHCO3 was less prominent in patients treated with iso-osmolar contrast than in those treated with other contrast agents. Recent studies suggest that iodixanol may be less nephrotoxic compared with some (but not all) low molecular weight contrast agents and further studies are warranted to assess the interaction between the type of contrast agent used and the hydration strategy. These post-hoc analyses (meta-regressions, subset analyses) must be considered exploratory and hypothesis generating since they are based on a small number of trials and no adjustment for multiple comparisons was made.
The presented overall benefit of NaHCO3 may also be slightly overestimated by the two trials that were stopped early (both because of an overwhelming beneficial effect in the treatment group). Early stopping is controversial and it can lead to an overestimation of a treatment effect . However, the early stopped trials are rather small, and their overall influence therefore limited. Even after exclusion of these two studies, the overall benefit of NaHCO3 persists.
The importance of publication bias in meta-analysis in general and in this field in particular has been highlighted in the past. The overall magnitude of CIN reduction was clearly greater in published studies compared with unpublished studies. The strength of this study is the inclusion of all available unpublished data and therefore represents the most robust analysis in this field so far. However, even after a comprehensive search for, and inclusion of these unpublished studies, formal testing indicates a likelihood of more unpublished data. Based on statistical estimations, the number and overall effect of unpublished data are probably limited. The treatment effect based on imputed estimated unpublished studies still supports superiority of NaHCO3 (OR 0.62; 95% CI 0.40–0.97). The use of NaHCO3 is likely associated with a reduction in the incidence of CIN, which may be somewhat overestimated by unpublished studies.
On the other hand, the inclusion of many unpublished studies to overcome the problem of publication bias, introduces the possibility of including lower-quality data that has not undergone robust peer review. However, these trials have all been presented at scientific meetings, published in an abstract format and have undergone a limited peer-review.
While most randomized data suggest either a lower risk of CIN with NaHCO3 or no difference compared with NS, a large observational study from the Mayo Clinic has raised the possibility of potential harm with this strategy. In a retrospective study of 7,911 patients encompassing 11,516 cases of contrast exposure, the risk of CIN among patients treated with NaHCO3 was significantly increased compared with the untreated group (OR 3.0, P < 0.05) . Only a small proportion of patients (489 out of 7,977) were pre-treated with NaHCO3 and the extreme results of this study in contrast to the randomized data suggest that the conclusions may be driven by unrecognized confounders. It is reassuring that despite multiple trials performed in various countries, none has demonstrated superiority of saline-based hydration and the overall odds of mortality and need for renal replacement therapy albeit exceedingly low overall, are lower in the NaHCO3 arm. The cumulative analysis further supports this conclusion, at no particular time point since the first publication of Merten et al. , the OR pointed towards an inferiority of NaHCO3. However, this also illustrates the fact that the effect of NaHCO3 probably was significantly overestimated at first and the inclusion of the recent studies seems to be leading us closer to a more accurate estimate of effect size.
It remains unclear whether there is a dose effect and whether alkalinization is the underlying beneficial mechanism. Six studies monitored the degree of alkalinization (pH urine or blood) [11, 15, 19, 20, 22, 24]. All but one found a significant increase in pH with exception of Lin et al. , which in fact was the only one among them not to find a benefit of NaHCO3. Therefore, it could be hypothesized that NaHCO3 should be dosed to achieve urinary alkalinization. Promisingly, the study of Tamura et al.  indicates that even a single bolus of NaHCO3 administered just prior to contrast administration may be effective and such a protocol could be easily used in most healthcare settings. The efficacy of this approach, however, needs validation in larger studies before it can be recommended for widespread use.
Our meta-analysis suggested a significant benefit of using NaHCO3-based hydration for prophylaxis of CIN although the magnitude of the benefit may have been overestimated by earlier studies. However, the lack of any study to date showing superiority of saline-based hydration suggests that NaHCO3-based hydration should be considered the optimal hydration in high-risk patients undergoing exposure to iodinated contrast.
randomized controlled trial
We are especially grateful to Whitney Townsend, Librarian, Taubman Medical Library, University of Michigan, for her valuable inputs during the literature search. We thank Dr M. Lin and Dr Phuong-Chi Pham, Olive View-UCLA Medical Center, Sylmar, CA, USA, and Dr Lina Shaik and Dr Itzchak Slotki, Shaare Zedek Medical Center, Jerusalem, Israel, for providing important information on their studies.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.